Cidara Therapeutics, Inc. (CDTX)

NASDAQ: CDTX · IEX Real-Time Price · USD

0.730

-0.095 (-11.48%)

At close: Apr 16, 2024, 4:00 PM

0.711

-0.019 (-2.67%)

After-hours: Apr 16, 2024, 6:18 PM EDT

Cidara Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Revenue	64.29	49.57	12.07	20.92	0	0	0	0	0	0
Revenue Growth (YoY)	29.69%	310.81%	-42.30%	-	-	-	-	-	-	-
Gross Profit	64.29	49.57	12.07	20.92	0	0	0	0	0	0
Selling, General & Admin	18.49	18.74	15.9	16.24	14.14	12.9	12.74	8.84	3.31	0.27
Research & Development	75.52	73.09	68.02	46.4	49.14	42.82	35.7	23.48	6.71	0.81
Other Operating Expenses	0	0	0	0	0	0	0	0	1.61	0
Operating Expenses	94.01	91.83	83.92	62.64	63.29	55.72	48.44	32.31	11.62	1.08
Operating Income	-29.72	-42.26	-71.85	-41.72	-63.29	-55.72	-48.44	-32.31	-11.62	-1.08
Interest Expense / Income	-0.19	0.21	0.26	-0.22	-0.63	0.01	0.27	0.12	-0.09	0.1
Other Expense / Income	-	-	-	-0.41	-3.64	-	-0.54	-0.24	0.36	0.17
Pretax Income	-29.53	-42.47	-72.11	-41.09	-59.02	-55.73	-48.17	-32.19	-11.89	-1.34
Income Tax	0.27	0	0	0	0	0	0	0	0	0
Net Income	-29.8	-42.47	-72.11	-41.09	-59.02	-55.73	-48.17	-32.19	-11.89	-1.34
Preferred Dividends	0	0	2.76	0	10.33	0	0	0	0	0
Net Income Common	-29.8	-42.47	-74.87	-41.09	-69.35	-55.73	-48.17	-32.19	-11.89	-1.34
Shares Outstanding (Basic)	70	52	42	30	26	18	14	10	1	0
Shares Outstanding (Diluted)	70	52	42	30	26	18	14	10	1	0
Shares Change	33.18%	26.22%	38.83%	15.71%	47.82%	20.79%	46.05%	1110.00%	153.29%	-
EPS (Basic)	-0.43	-0.81	-1.80	-1.37	-2.68	-3.18	-3.32	-3.25	-14.51	-4.15
EPS (Diluted)	-0.43	-0.81	-1.80	-1.37	-2.68	-3.18	-3.32	-3.25	-14.51	-4.15
Free Cash Flow	-28.59	-25.27	-54.6	-28.57	-56.88	-50.22	-40.17	-27.13	-8.7	-1.05
Free Cash Flow Per Share	-0.41	-0.48	-1.31	-0.95	-2.20	-2.87	-2.77	-2.73	-10.61	-3.24
Gross Margin	100.00%	100.00%	100.00%	100.00%	-	-	-	-	-	-
Operating Margin	-46.23%	-85.24%	-595.42%	-199.49%	-	-	-	-	-	-
Profit Margin	-46.35%	-85.67%	-620.48%	-196.47%	-	-	-	-	-	-
Free Cash Flow Margin	-44.47%	-50.98%	-452.45%	-136.59%	-	-	-	-	-	-
EBITDA	-29.58	-42.07	-71.56	-40.99	-59.12	-55.05	-47.16	-31.61	-11.8	-1.25
EBITDA Margin	-46.00%	-84.86%	-593.05%	-195.96%	-	-	-	-	-	-
Depreciation & Amortization	0.14	0.19	0.29	0.33	0.52	0.67	0.73	0.46	0.18	0
EBIT	-29.72	-42.26	-71.85	-41.31	-59.65	-55.72	-47.89	-32.07	-11.98	-1.25
EBIT Margin	-46.23%	-85.24%	-595.42%	-197.53%	-	-	-	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).